Mitochondrial Enzyme Cmpk2 Protects Against Severe Lung Injury in Mice

Acute respiratory distress syndrome (ARDS) and acute lung injury represent life-threatening conditions characterized by severe breathing difficulties and lung inflammation. This study investigated the role of Cmpk2, a mitochondrial enzyme involved in cellular metabolism, in protecting against bacterial lung infections.

Researchers used mice genetically engineered to lack the Cmpk2 enzyme and exposed them to Pseudomonas aeruginosa, a dangerous bacteria that commonly causes pneumonia. They found that mice without Cmpk2 experienced significantly worse lung damage, increased inflammation, and higher levels of inflammatory molecules compared to normal mice.

The key discovery was that Cmpk2 enhances the ability of neutrophils (a type of white blood cell) to engulf and destroy bacteria through a process called phagocytosis. Single-cell analysis of human ARDS patients revealed that Cmpk2 is highly expressed in neutrophils, suggesting its importance in human disease. The protective effects appear to work through the STING pathway, a cellular signaling system involved in immune responses.

These findings suggest that Cmpk2 could serve as a therapeutic target for treating severe lung infections and ARDS. By understanding how this mitochondrial enzyme supports immune function, researchers may develop new treatments that enhance the body's natural ability to fight respiratory infections and reduce lung inflammation.